Adastra Pharmaceuticals, Inc is a privately held pharmaceutical company based in San Diego, California and Princeton, New Jersey. The company focuses upon the clinical and commercial development of proprietary medicines for the treatment of cancer. The Adastra development programs are guided by world-class key opinion leaders and advisors. The lead candidate, TG02, is currently in Phase 1b development in cancers with Myc overexpression. Adastra holds worldwide rights to TG02 excluding China and Russia and patent protection through 2034 with extensions. In addition to developing TG02, Adastra will continue to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies. The core management team has successfully transitioned their years of experience developing oncology drugs in large pharmaceutical companies into the entrepreneurial biotech environment. Adastra is backed by a syndicate of premier life sciences investors, including: Domain Associates, Lee’s Pharma, Morgenthaler Ventures, ProQuest Investments, and RusnanoMedInvest.
TG02 potently inhibits cyclin-dependent kinase 9 leading to apoptotic effect and modulation of the cell cycle. TG02 blocks the activity of RNA polymerase II, leading to depletion of the key cancer cell survival protein, c-Myc. In glioblastoma cell lines and in vivo models, TG02 has demonstrated broad anti-tumor activity.